← boardnext 2026-08
CADL
Candel Therapeutics, Inc.distress 4/10 · elevated risk$10.040%today-3% from 52w high
Oncology 2
Lead: localized prostate cancer · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$195M
Runway
4.1 yrs
Shares 1y
+34%
Price & events
+59.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.5%
1D
+5.9%
1W
+10.6%
1M
+42.6%
3M
+61.9%
6M
+44.3%
1Y
+53.3%
2Y
—
5Y
+43.4%
All
Overview
- Market Cap
- $735.63M
- Enterprise Value
- $542.53M
- Volume
- 60.30K
- 52 Week Range
- $4.42 – $10.36
- Total Shares
- 73.27M
- Float Shares
- 56.81M
- Short %
- 28.68%
- % Held by Insiders
- 15.53%
- % Held by Institutions
- 60.02%
- RVOL
- 0.03x
- Beta
- -0.51
Pipeline stages · 1 programs
Aglatimagene Besadenovec, Valacyclovir, Pembrolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-09-15 | Phase 2 | aglatimagene besadenovec, valacyclovir | Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma) | 45 | recruiting |
| 2031-10-22 Estimated 50% readout ~2032-01-05 | Phase 3 | Aglatimagene Besadenovec, Valacyclovir, Pembrolizumab | Non-squamous, Non-Small Cell Lung Cancer | — | recruiting |
| 2025-12 | Phase 2 | Aglatimagene besadenovec | Borderline Resectable Pancreatic Adenocarcinoma | 54 | active not recruiting |
Catalyst news & presentations · 11
- Q4 2026Guided 70%regulatory submissionFiled (NDA/BLA)CAN-2409 · BLA submission for CAN-2409 in prostate cancerSEC 8-K
- AUA 2026 Annual MeetingGuided 40%conferencedata presentationsecondaryAglatimagene Besadenovec (CAN-2409) · Presentation of extended clinical benefit over multiple clinical endpoints from Phase 3 trial under prolonged follow-up.PR wire
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- May 15, 2026conferencedata presentationsecondaryPhase 3aglatimagene besadenovec · Extended follow-up data from Phase 3 trial presented at AUA 2026 Annual Meeting.SEC 8-K
- 2026-02-19partnershipCAN-2409 · Announced $100M royalty funding agreement with RTW Investments contingent on FDA approval for localized prostate cancer.SEC 8-K
- 2025-2026regulatory submissionFiled (NDA/BLA)CAN-2409 · BLA filing anticipated in 2025-2026SEC 8-K
- fourth quarter of 2025readoutPhase 1CAN-3110 · Final overall survival readout for Phase 1b trialSEC 8-K
- 2025-12-05conferencedata presentationsecondaryVirtual R&D Day presenting pipeline overviewSEC 8-K
- 2025-10-14partnershipEntered $130M Loan and Security Agreement with Trinity Capital; drew $50M first tranche.SEC 8-K
- Tuesday, June 3, 2025; 9:45 AM - 12:45 PM CTconferencedata presentationsecondaryPhase 3CAN-2409 · Oral presentation of Phase 3 data at ASCO 2025.SEC 8-K
- first quarter of 2025readoutPhase 2CAN-2409 · Final overall survival phase 2a data readoutsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $21 (+104% upside) · 8 analysts
- 2026-07-13StifelBuy
- 2026-04-20Cantor FitzgeraldOverweight
- 2026-03-18CitigroupBuy
- 2026-03-13CitigroupBuy
- 2026-03-13Canaccord GenuityBuy
- 2025-12-08Stephens & Co.Overweight
Competitors — localized prostate cancer
- BAYRY— · D2
Recent news
- 2026-07-21Aurelius Township threatens to leave CADL library system - Lansing State Journal
- 2026-07-20Go beyond the book with CADL’s summer reading challenge and concerts - WILX
- 2026-07-20Summer Check-in with CADL - WILX
- 2026-07-19Dow, S&P 500, Nasdaq Futures Rise As Traders Eye Supreme Court Tariff Verdict, GDP Data: Why GRAL, RIG, CADL, CELH, ARDX Are Trending - Stocktwits
- 2026-07-18ETFs Investing in Candel Therapeutics, Inc. Stocks - TradingView
- 2026-07-18Candel Therapeutics Insider Ups Holding By 14% During Year - simplywall.st
- 2026-07-17CADL Q1 2026 Earnings: Narrower Loss Surprises Analysts, Yet Stock Slips - Earnings Call Highlights - dars.gov.et
- 2026-07-14Stifel Initiates Candel Therapeutics(CADL.US) With Buy Rating, Announces Target Price $22 - 富途牛牛
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.